Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer
NCT04707287 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 382
Last updated 2021-01-14
Summary
Null hypothesis: Histological grade of tumour bears no relation with the status of sex hormone receptors.
Alternate hypothesis: Both the histological grade of tumour and expression of sex steroid receptors are directly related to each other The investigators aim to;
1. see the relationship of sex steroid receptors with the histological grade of breast cancer.
2. evaluate the efficacy of steroid receptors as a prognostic factor
Conditions
Interventions
- OTHER
-
No Intervention
No intervention used. This is observational study
Sponsors & Collaborators
-
Liaquat University of Medical & Health Sciences
lead OTHER
Principal Investigators
-
Fazila Hashmi · Liaquat University of Medical and Health Sciences Jamshoro Pakistan
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-07-01
- Primary Completion
- 2021-01-01
- Completion
- 2021-01-15
Countries
- Pakistan
More Related Trials
-
Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy
NCT00913016 ·Status: UNKNOWN
-
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
NCT01758146 ·Status: UNKNOWN ·Phase: PHASE3
-
Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer
NCT02263846 ·Status: COMPLETED
-
Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women
NCT01069211 ·Status: UNKNOWN
-
Study of Breast Cancer Prevention by Letrozole in High Risk Women
NCT00579826 ·Status: COMPLETED ·Phase: PHASE2
-
Patient's Anastrozole Compliance to Therapy Programme
NCT00555867 ·Status: TERMINATED
-
Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients
NCT02812277 ·Status: UNKNOWN
-
Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07
NCT01281137 ·Status: COMPLETED
-
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
NCT00573755 ·Status: TERMINATED ·Phase: PHASE2
-
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
NCT01080170 ·Status: COMPLETED
-
Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer
NCT02506361 ·Status: RECRUITING
-
CYP2D6 Genotype on the Clinical Effect of Tamoxifen
NCT00973037 ·Status: UNKNOWN
-
RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer
NCT01208441 ·Status: TERMINATED ·Phase: PHASE1
-
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
NCT00382070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
NCT00237133 ·Status: COMPLETED ·Phase: PHASE4
-
The Performance of Patient Support Program in Early Stage Breast Cancer
NCT00769080 ·Status: COMPLETED
-
The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer
NCT05507398 ·Status: UNKNOWN ·Phase: PHASE4
-
Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
NCT01072318 ·Status: UNKNOWN ·Phase: PHASE4
-
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
NCT01237327 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Observational Study of Antitumor Activity Correlation Between Hormonal Therapy and Expression miRNA100
NCT02950207 ·Status: UNKNOWN
-
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
NCT02598557 ·Status: COMPLETED ·Phase: PHASE2
-
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
NCT00256698 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)
NCT01908556 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
NCT00796107 ·Status: TERMINATED ·Phase: PHASE2
-
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
NCT07019363 ·Status: RECRUITING ·Phase: PHASE3